Supriya Lifescience has received the Establishment Inspection Report (EIR) for its manufacturing facility located at Lote, Parshuram Industrial Area, Maharashtra, India, indicating ‘Voluntary Action Indicated' (VAI), signifying a successful completion of the inspection.
The United States Food and Drug Administration (USFDA) conducted an inspection at the company’s manufacturing facility located at Lote from February 02, 2026 to February 06, 2026. The inspection concluded with the issuance of a Form 483 containing one minor observation. The company has adequately addressed the observation.
Supriya Lifescience is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (APIs), with a focus on research and development.
